오스테오닉

226400KOSDAQ의료용 기기 제조업

63.5 / 100

Reference Date: 2026-04-13

Financial Score23.0 / 40

News Sentiment22.5 / 25

Momentum8.0 / 20

Disclosure10.0 / 15

AI Analysis: PER is significantly undervalued vs. peers but the high debt ratio poses financial risk. Slightly up 2.2% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Osteonic produces and sells medical devices (implants) made of metal or biocompatible materials, used for bone fixation, replacement, and adjustment in various body parts such as the skull, jaw, trauma sites, and joints. While metal-based products dominate sales, biocomposite materials are gaining increasing share.

Number of Employees

197people

Average Salary

41.5M KRW

Score Calculation Basis

Detailed Financial Score

PER

17.70Industry Average 26.526.5Point

Lower than industry avg (good)

PBR

2.02Industry Average 1.702.5Point

Higher than industry avg (caution)

ROE

11.82Industry Average 8.004.0Point

In line with industry avg

Debt Ratio

19.29Industry Average 10.950.5Point

1.8x industry avg (risky)

Trend 2023~20259.5 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲27.9% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲35.5% (2-year basis)

ROE Trend

3.5 / 4

Avg ROE 10.1% (improving, 3yr)

Detailed News Sentiment

1 totalPositive 1Neutral 0Negative 0Average Sentiment Score 90

Positive
오스테오닉, 척추 임플란트 FDA 승인…짐머 매출 탄력·美 성장 가속
오스테오닉은 척추 임플란트 제품의 미국 FDA 승인을 획득하며 짐머 바이오메트와의 협력 매출 탄력 및 미국 시장 성장을 가속화할 것으로 기대된다.

Detailed Momentum

52-week position3.0Point

52w lower range (39%)

Current 6,620Won52-week high 8,14052-week low 5,630

1-month return4.0Point

1m +2.16% (slight rise)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

3 totalPositive 0Neutral 3Negative 0

Neutral정기주주총회결과2026-03-27
Neutral사업보고서 (2025.12)2026-03-19
Neutral감사보고서제출2026-03-19